A new frontier AI company called Recursive Superintelligence has emerged from stealth with $650 million in funding and an unusually ambitious goal: building AI systems capable of improving themselves ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and ...

Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST Salt Lake City, UT, April 29, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

The recursive least-squares (RLS) adaptive filtering algorithm is frequently used in system identification problems. The popularity of this algorithm is mainly related to its fast convergence rate. In ...

edge(0,1,3). edge(1,0,3). edge(0,2,6). edge(2,0,6). edge(0,3,5). edge(3,0,5). edge(1,4,9). edge(4,1,9). edge(1,5,8). edge(5,1,8). edge(2,6,12). edge(6,2,12). edge(2,7 ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec Stranahan, an analyst at Bank of America Securities, maintained a Hold rating on ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...